P. Bolli

发表

Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children.

Alexander G Logan, Simon L Bacon, Michael D Hill, 2018, The Canadian journal of cardiology.

THERAPY AND PREVENTION

P. Erne, T. Resink, R. Ritz, 2005 .

The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.

Simon L Bacon, Michael D Hill, Pierre Larochelle, 2013, The Canadian journal of cardiology.

New algorithm for the diagnosis of hypertension.

F. McAlister, B. Hemmelgarn, S. Tobe, 2005, American journal of hypertension.

Pressure-volume-temperature relationships of solid and molten poly(ethylene terephthalate)

P. Zoller, P. Bolli, 1980 .

Alpha-adrenoceptors, adrenaline, and exaggerated vasoconstrictor response to stress in essential hypertension.

F. Bühler, P. Bolli, W. Kiowski, 1983, Chest.

High normal blood pressure and prehypertension: the debate continues.

B. Hemmelgarn, S. Tobe, G. Tremblay, 2007, The Canadian journal of cardiology.

[Disturbance of intestinal absorption following metformin therapy (observations on the mode of action of biguanides].

P. Bolli, P. Berchtold, U. Arbenz, 1969, Diabetologia.

Lifestyle modifications to prevent and control hypertension. 6. Recommendations on potassium, magnesium and calcium. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation o

P. Hamet, E. Burgess, A. Chockalingam, 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.

Lawrence A Leiter, P. McFarlane, E. Schiffrin, 2013, The Canadian journal of cardiology.

The 2001 Canadian recommendations for the management of hypertension: Part one--Assessment for diagnosis, cardiovascular risk, causes and lifestyle modification.

E. Schiffrin, F. McAlister, R. Touyz, 2002, The Canadian journal of cardiology.

A preliminary clinical trial of Prazosin: a new oral antihypertensive agent.

P. Bolli, F. O. Simpson, 1974, The New Zealand medical journal.

Prazosin: preliminary clinical and pharmacological observations.

D. Lee, P. Bolli, F. O. Simpson, 1975, Clinical science and molecular medicine. Supplement.

Effects of prazosin in patients with hypertension

P. Bolli, F. O. Simpson, A. Wood, 1976, Clinical pharmacology and therapeutics.

Prazosin in normal subjects: plasma levels, blood pressure and heart rate.

P. Bolli, F. O. Simpson, A. Wood, 1976, British journal of clinical pharmacology.

Temperature-dependence of LDL binding and activation of human platelets.

P. Bolli, R. Bose, P. Katzman, 1991, Thrombosis research.

Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients.

P. Erne, L. Block, F. Bühler, 1984, The American journal of medicine.

Relationship of blood pressure to sodium excretion in a population survey.

G. Spears, H. Waal-Manning, P. Bolli, 1978, Clinical science and molecular medicine. Supplement.

The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part I - blood pressure measurement, diagnosis and assessment of risk.

E. Schiffrin, F. McAlister, B. Hemmelgarn, 2010, The Canadian journal of cardiology.

The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk.

E. Schiffrin, F. McAlister, B. Hemmelgarn, 2007, The Canadian journal of cardiology.

The question of the role of ethnicity on cardiovascular risk: does it matter where we come from?

P. Bolli, 2005, Journal of hypertension.

The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of risk.

E. Schiffrin, F. McAlister, B. Hemmelgarn, 2006, The Canadian journal of cardiology.

1999 Canadian recommendations for the management of hypertension including Case-based applications of the recommendations

Lawrence A Leiter, R. Haynes, J. Spence, 1999 .

Dawes M, Pluye P, Shea L, Grad R, Greenberg A, Nie J-Y; The Identification of Clinically Important Elements within Medical Journal Abstracts: Patient-Population-Problem, Exposure-Intervention, Comparison, Outcome, Duration, & Results (PECODR). Informatics in Primary Care 2007;15(1):9-16.

K. Mann, S. Rabkin, L. Cloutier, 2007 .

Calcium antagonists and the second drug for hypertensive therapy.

P. Erne, F. Bühler, P. Bolli, 1986, The American journal of medicine.

The Role of Adiponectin in Endothelial Dysfunction and Hypertension

P. Bolli, M. Velasco, E. Rojas, 2014, Current Hypertension Reports.

Correlation of platelet calcium with blood pressure. Effect of antihypertensive therapy.

P. Erne, F. Bühler, P. Bolli, 1984, The New England journal of medicine.

Masked hypertension: a common but insidious presentation of hypertension.

A. Chockalingam, M. Myers, P. Bolli, 2006, The Canadian journal of cardiology.

Factors influencing the hypotensive effects of calcium antagonists.

P. Erne, O. Bertel, P. Bolli, 1983, Hypertension.

The contribution of alpha-1 and alpha-2-adrenoceptor mediated vasoconstriction in essential hypertension as assessed by forearm venous occlusion plethysmography

F. Bühler, P. Bolli, W. Kiowski, 1987 .

Elevated plasma adrenaline reflects sympathetic overactivity and enhanced alpha-adrenoceptor-mediated vasoconstriction in essential hypertension.

F. Bühler, P. Bolli, W. Kiowski, 1981, Clinical science.

The Milton survey: Part 1, General methods, height, weight and 24-hour excretion of sodium, potassium, calcium, magnesium and creatinine.

G. Spears, A. Goulding, H. Waal-Manning, 1978, The New Zealand medical journal.

Acute and chronic sympathetic reflex activation and antihypertensive response to nifedipine.

P. Erne, O. Bertel, F. Bühler, 1986, Journal of the American College of Cardiology.

Effects of a new long-acting beta-blocker bopindolol (LT 31-200) on blood pressure, plasma catecholamines, renin and cholesterol in patients with arterial hypertension

F. Bühler, P. Bolli, F. Amann, 2004, European Journal of Clinical Pharmacology.

Comparative effects of haemodialysis and haemofiltration on plasma atrial natriuretic peptide.

P. Erne, P. Bolli, A. Raine, 1989, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Age, race, blood pressure and renin: predictors for antihypertensive treatment with calcium antagonists.

P. Erne, F. Bühler, P. Bolli, 1985, The American journal of cardiology.

Vasodilatory effect of nicardipine and verapamil in the forearm of hypertensive as compared with normotensive man.

F. Bühler, P. Bolli, U. Hulthén, 1985, British journal of clinical pharmacology.

Enhanced vasodilatation in essential hypertension by calcium channel blockade with verapamil.

F. Bühler, P. Bolli, W. Kiowski, 1982 .

Enhanced Vasodilatation in Essential Hypertension by Calcium Channel Blockade with Verapamil

P. Bolli, W. Kiowski, F. Amann, 1982, Hypertension.

Lack of Beta‐adrenoreceptor Hypersensitivity After Abrupt Withdrawal of Long‐term Therapy with Oxprenolol

E. Raeder, P. Bolli, F. Buhler, 1981, Circulation.

Use of calcium antagonists as monotherapy in the management of hypertension.

P. Erne, F. Bühler, P. Bolli, 1984, The American journal of medicine.

Enhanced Alpha‐Adrenoreceptor‐Mediated Vasoconstriction in Essential Hypertension

P. Bolli, W. Kiowski, F. Buhler, 1981, Hypertension.

Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure.

P. Erne, F. Bühler, P. Bolli, 1986, The New England journal of medicine.

β-Blockers and Calcium Antagonists

F. Bühler, P. Bolli, W. Kiowski, 1983, Drugs.

Parallel Reduction of Calcium‐Influx‐Dependent Vasoconstriction and Platelet‐Free Calcium Concentration with Calcium Entry and β‐Adrenoceptor Blockade

P. Erne, R. Ritz, P. Bolli, 1984, Journal of cardiovascular pharmacology.

Inhibition of the arteriolar smooth muscle NA+ -K+-pump induces an enhanced vasoconstriction in borderline but not in established essential hypertension.

F. Bühler, P. Bolli, W. Kiowski, 1983, General pharmacology.

Calcium channel inhibitors for identification of mechanisms and treatment of hypertension.

F. Bühler, P. Bolli, U. Hulthén, 1982, Journal of cardiovascular pharmacology.

The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk.

E. Schiffrin, B. Hemmelgarn, K. Mann, 2005, The Canadian journal of cardiology.

Greater Antihypertensive Efficacy of the Calcium Channel Inhibitor Verapamil in Older and Low Renin Patients

F. Bühler, P. Bolli, W. Kiowski, 1982 .

Calcium antagonist induced vasodilation in peripheral, coronary and cerebral vasculature as important factors in the treatment of elderly hypertensives.

P. Erne, D. Conen, F. Bühler, 1987, European heart journal.

The place of the calcium antagonist verapamil in antihypertensive therapy.

F. Bühler, P. Bolli, W. Kiowski, 1982, Journal of cardiovascular pharmacology.

The 2000 Canadian recommendations for the management of hypertension: part two--diagnosis and assessment of people with high blood pressure.

F. McAlister, K. Zarnke, K. Mann, 2001, The Canadian journal of cardiology.

The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of risk.

E. Schiffrin, F. McAlister, B. Hemmelgarn, 2004, The Canadian journal of cardiology.

Pathophysiological role of atrial natriuretic peptide in man.

P. Erne, T. Resink, F. Bühler, 1988, Pharmacological research communications.

Modulation of left ventricular hypertrophy by dietary salt and inhibition of angiotensin converting enzyme

P. G. Fernandez, S. Vasdev, P. Bolli, 1988, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

Hemodynamic and counterregulatory effects of calcium antagonists in hypertension.

P. Erne, F. Bühler, P. Bolli, 1988, Journal of cardiovascular pharmacology.

ROLE OF CALCIUM ANTAGONISTS IN THE TREATMENT OF HYPERTENSION

P. Erne, F. Follath, P. Bolli, 1986 .

Mechanisms of Action and Clinical Use of Calcium Antagonists in Hypertension

P. Erne, F. Bühler, P. Bolli, 1989, Circulation.

Plasma lipid fractions during long-term monotherapy with the ISA-containing beta-adrenoceptor blocker bopindolol in hypertensive patients.

H. Staehelin, F. Bühler, P. van Brummelen, 1984, British journal of clinical pharmacology.

Intrarenal blood flow distribution in the genetically hypertensive rat.

D. Jones, P. Bolli, A. Wallis, 1980, Nephron.

Greater vasodilator responsiveness to atrial natriuretic peptide in low-renin essential hypertensives.

P. Erne, T. Resink, F. Bühler, 1987, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

Decrease in alpha-adrenoceptor-mediated vasoconstriction parallels the antihypertensive response to propranolol in patients with normal renin essential hypertension.

F. Bühler, P. Bolli, W. Kiowski, 1981, Clinical science.

Calcium influx blockers in the treatment of essential hypertension.

F. Bühler, P. Bolli, U. Hulthén, 2009, Acta medica Scandinavica. Supplementum.

The 24 h blood pressure responses of hypertensives to a once-a-day cilazapril regimen.

P. G. Fernandez, P. Bolli, C. Lee, 1990, The Canadian journal of cardiology.

MODERATE HYPERTENSION

F. Gutzwiller, F. Paccaud, P. Bolli, 1985, The Lancet.

Cardiac and Vascular &bgr;‐Adrenoceptor‐Mediated Responses Before and During Treatment with Bisoprolol or Atenolol

F. Bühler, P. Bolli, F. Müller, 1985, Journal of cardiovascular pharmacology.

The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy.

Lawrence A Leiter, P. McFarlane, E. Schiffrin, 2012, The Canadian journal of cardiology.

Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients.

P. Erne, L. Block, F. Bühler, 1984 .

Verapamil-induced vasodilator response is enhanced in essential hypertension.

F. Bühler, P. Bolli, W. Kiowski, 1983, General pharmacology.

Atenolol v placebo in mild hypertension: renal metabolic and stress antipressor effects.

H. Waal-Manning, P. Bolli, H. Waal‐Manning, 1980, British journal of clinical pharmacology.

The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - blood pressure measurement, diagnosis and assessment of risk.

E. Schiffrin, F. McAlister, B. Hemmelgarn, 2006, The Canadian journal of cardiology.

Applying the 2005 Canadian Hypertension Education Program recommendations: 1. Diagnosis of hypertension

M. Myers, P. Bolli, D. McKay, 2005, Canadian Medical Association Journal.

Plasma catecholamines and cardiac, renal and peripheral vascular adrenoceptor-mediated responses in different age groups of normal and hypertensive subjects.

R. Landmann, O. Bertel, F. Bühler, 1980, Clinical and experimental hypertension.

Cholesterol reduction in cyclosporine-treated renal transplant patients: effect on platelet-derived growth factor levels and platelet activation.

D. Rush, P. Bolli, R. Bose, 1997, Transplantation proceedings.

Calcium antagonism--a new concept for treating essential hypertension.

P. Erne, F. Bühler, P. Bolli, 1986, The American journal of cardiology.

Atrial Natriuretic Peptide and Atrial Pressure in Patients with Congestive Heart Failure

P. Erne, D. Phil., P. Bolli, 1987 .

Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics.

P. Erne, D. Conen, F. Bühler, 1985, Journal of cardiovascular pharmacology.

Free calcium concentration in platelets closely relates to blood pressure in normal and essentially hypertensive subjects.

P. Erne, F. Bühler, P. Bolli, 1984, Hypertension.

Experience with labetalol in hypertension.

P. Bolli, F. O. Simpson, A. Wood, 1976, British journal of clinical pharmacology.

Electrocardiographic Changes During Antihypertensive Therapy in the International Prospective Primary Prevention Study in Hypertension

P. Bolli, F. Buhler, F. Burkart, 1987, Hypertension.

Apparatus for measuring pressure–volume–temperature relationships of polymers to 350 °C and 2200 kg/cm2

H. Ackermann, P. Zoller, P. Bolli, 1976 .

Reducing Cardiovascular Risk with HMG CoA Reductase Inhibitors, Potential Contribution from Platelets

P. Bolli, D. Mymin, R. Bose, 2003 .

Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring.

F. Leenen, J. Tanner, P. Bolli, 1997, The Canadian journal of cardiology.

(-)-Adrenaline-induced, calcium-dependent phosphorylation of proteins in human platelets.

P. Erne, L. Block, F. Bühler, 1985, The Journal of clinical investigation.

Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension.

P. McFarlane, E. Schiffrin, A. Logan, 2016, The Canadian journal of cardiology.

I. Accurate Measurement of Blood Pressure

S. Daskalopoulou, K. Zarnke, K. Dasgupta, 2016 .

A New Algorithm for the Diagnosis of Hypertension in Canada.

Guy Tremblay, Maxime Lamarre-Cliche, Stella S Daskalopoulou, 2015, The Canadian journal of cardiology.

MEthods of ASsessing blood pressUre: identifying thReshold and target valuEs (MeasureBP): A Review & Study Protocol

G. Bartlett, E. Schiffrin, B. Hemmelgarn, 2015, Current Hypertension Reports.

Treatment of dyslipidemia: the problem of reaching the goal.

P. Bolli, 2014, Atherosclerosis.

The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1--blood pressure measurement, diagnosis and assessment of risk.

E. Schiffrin, F. McAlister, B. Hemmelgarn, 2009, The Canadian journal of cardiology.

The vasodilator potency of atrial natriuretic peptide in man.

P. Erne, T. Resink, R. Ritz, 1987, Circulation.

The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.

Simon L Bacon, Michael D Hill, Pierre Larochelle, 2014, The Canadian journal of cardiology.

Position of calcium antagonists in antihypertensive therapy.

P. Erne, F. Bühler, P. Bolli, 1985, Journal of cardiovascular pharmacology.

Recommendations on potassium , magnesium and calcium

Richard Lewanczuk, Pavel Hamet, Arun Chockalingam, 1999 .

Clonidine in menopausal flushing: a double-blind trial.

P. Bolli, F. O. Simpson, 1975, The New Zealand medical journal.

The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy.

Simon L Bacon, Martin G Myers, Michael D Hill, 2011, The Canadian journal of cardiology.

Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults.

Lawrence A Leiter, P. McFarlane, E. Schiffrin, 2017, The Canadian journal of cardiology.

Impact of smoking on heart attacks, strokes, blood pressure control, drug dose, and quality of life aspects in the International Prospective Primary Prevention Study in Hypertension.

F. Bühler, P. Bolli, K. Vesanen, 1988, American heart journal.

New Algorithm for the Diagnosis of Hypertension: Canadian Hypertension Education Program Recommendations (2005)

F. McAlister, B. Hemmelgarn, S. Tobe, 2005 .

Treatment resistant hypertension.

P. Bolli, 2008, American journal of therapeutics.

Hemodynamic and Reflex Responses to Acute and Chronic Antihypertensive Therapy with the Calcium Entry Blocker Nifedipine

P. Erne, R. Ritz, O. Bertel, 1983, Hypertension.

6. Recommendations on potassium, magnesium and calcium

Pavel Hamet, Arun Chockalingam, P. Hamet, 1999 .

Targeting Hypertension in Patients with Cardiorenal Metabolic Syndrome

P. Bolli, M. Velasco, E. Rojas, 2012, Current Hypertension Reports.

Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children.

Lawrence A Leiter, P. McFarlane, E. Schiffrin, 2020, The Canadian journal of cardiology.

Do Recommendations for the Management of Hypertension Improve Cardiovascular Outcome? The Canadian Experience

N. Campbell, P. Bolli, 2011, International journal of hypertension.

Experience with prazosin in the treatment of hypertension.

P. Bolli, F. O. Simpson, 1975, Postgraduate medicine.

Atrial antipressor natriuretic peptide: release mechanisms and vascular action in man.

P. Erne, T. Resink, F. Bühler, 1986, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

Exercise and resting blood pressure and heart rate changes 24 h after dosing in patients with essential hypertension receiving 16/260 oxprenolol Oros once daily.

R. Ritz, F. Bühler, P. Bolli, 1985, British Journal of Clinical Pharmacology.

Hypertension Canada's 2016 CHEP Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention and Treatment of Hypertension

Lawrence A Leiter, P. McFarlane, A. Logan, 2016 .

Elevated adrenaline and increased alpha-adrenoceptor-mediated vasoconstriction in essential hypertension.

R. Landmann, F. Bühler, P. Bolli, 1982, Journal of cardiovascular pharmacology.

Cilazapril inhibits vascular responses to baroreflex-stimulated sympathetic neural activity in hypertensive patients.

P. G. Fernandez, S. Vasdev, P. Bolli, 1990, The Canadian journal of cardiology.

Antihypertensive Therapy with the Long‐Acting Calcium Antagonist Nitrendipine

P. Erne, L. Block, F. Bühler, 1984, Journal of cardiovascular pharmacology.

Adrenaline induces vasoconstriction through post-junctional alpha 2 adrenoceptors and this response is enhanced in patients with essential hypertension.

P. Erne, L. Block, F. Bühler, 1984, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

Fura-2 used as a probe to show elevated intracellular free calcium in platelets of Dahl-sensitive rats fed a high salt diet.

V. Ananthanarayanan, C. Triggle, S. Vasdev, 1988, Biochemical and biophysical research communications.

[Hematologic side effects of chloramphenicol and thiamphenicol].

P. Bolli, G. Keiser, U. Buchegger, 1972, Swiss medical weekly.

Calcium Antagonists for Identification of Mechanisms and Treatment in Patients with Essential Hypertension

P. Erne, P. Bolli, W. Kiowski, 1985 .

Abnormal Cellular Calcium Regulation in Essential Hypertension

P. Erne, V. Tkachuk, T. Resink, 1986, Journal of Cardiovascular Pharmacology.

Concomitant Digoxin Toxicity and Warfarin Interaction in a Patient Receiving Clarithromycin

P. G. Fernandez, M. Gooderham, P. Bolli, 1999, The Annals of pharmacotherapy.

Adrenaline and enhanced vasoconstriction in patients with essential hypertension.

F. Bühler, P. Bolli, W. Kiowski, 1988, Pharmacology & toxicology.

Blunting of Beta-Adrenoceptor-Mediated Cardiovascular Responses and Increasing Alpha-Receptor-Mediated Vasoconstriction: An Age-Dependent Transformation of Essential Hypertension

R. Landmann, O. Bertel, F. Bühler, 1980 .

Failure of prejunctional alpha 2-adrenoceptor stimulation to reduce norepinephrine release in normal man.

R. Ritz, F. Bühler, P. Bolli, 1983, General pharmacology.

Changing Role of Beta- and Alpha-Adrenoreceptor-Mediated Cardiovascular Responses in the Transition from High-Cardiac Output into a High-Peripheral Resistance Phase in Essential Hypertension

R. Landmann, O. Bertel, F. Bühler, 1981 .

Free calcium response to adrenaline in platelets of normal and hypertensive (untreated and treated) subjects.

P. Erne, A. Hefti, T. Resink, 1984, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension.

R B Haynes, J S Floras, M G Myers, 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Serum Lipid Profile Determines Platelet Reactivity to Native and Modified LDL-Cholesterol in Humans

P. Bolli, D. Mclean, D. Mymin, 1994, Thrombosis and Haemostasis.

The Milton Survey. 2. Blood pressure and heart rate.

G. Spears, H. Waal-Manning, P. Bolli, 1978, The New Zealand medical journal.

Verapamil-induced vasodilation is enhanced in essential hypertension.

F. Bühler, P. Bolli, W. Kiowski, 1982, Journal of cardiovascular pharmacology.

Angiotensin II Receptor Antagonists in Patients With Renal Failure and on Hemodialysis

P. Bolli, D. Allan, 1998 .

Clinical problem solving based on the 1999 Canadian recommendations for the management of hypertension.

Lawrence A Leiter, A. Logan, R. Haynes, 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Ischemic ECG changes are found more often in asymptomatic men with a coronary prone behaviour pattern.

K. Bättig, F. Bühler, P. Bolli, 1993, Journal of psychosomatic research.

The adrenaline-alpha 2-adrenoceptor-mediated vasoconstrictor axis.

P. Erne, F. Bühler, P. Bolli, 1985, Clinical science.

The Vasodilating Effect of Atrial Natriuretic Peptide in Normotensive and Hypertensive Humans

P. Erne, T. Resink, P. Bolli, 1988, Journal of cardiovascular pharmacology.

The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.

Lawrence A Leiter, P. McFarlane, E. Schiffrin, 2014, The Canadian journal of cardiology.

Cardioselective beta-blockade and renal function.

P. Bolli, H. Waal‐Manning, 1979, British medical journal.

Sympathetic Nervous System in Essential Hypertension and Antihypertensive Response to α2-Adrenoceptor Stimulation

P. Erne, P. Bolli, W. Kiowski, 1984, Journal of Cardiovascular Pharmacology.

Antihypertensive Response to Postsynaptic &agr;‐Blockade with Prazosin in Low‐ and Normal‐Renin Hypertension

F. Bühler, P. Bolli, F. Amann, 1980 .

Effectiveness of multidisciplinary patient counselling in reducing cardiovascular disease risk factors through nonpharmacological intervention: results from the Healthy Heart Program.

D. Simpson, P. Bolli, B. Dixon, 2004, The Canadian journal of cardiology.

Role of alpha-adrenoceptor-mediated vasoconstriction for antihypertensive beta-blockade.

F. Bühler, P. Bolli, F. Amann, 1982, Journal of cardiovascular pharmacology.

Treatment resistant hypertension.

P. Bolli, 2008, American journal of therapeutics.